A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.

Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378

The Brief Psychiatric Rating Scale.

Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090

A Multiple Comparison Procedure for Comparing Several Treatments with a Control

Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 6,097

A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265

A Rating Scale for Drug-Induced Akathisia

Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040

Research diagnoses for tardive dyskinesia.

Schooler, N. R., & Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040080014 · Cited by 951

What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

Kemp, A. S., Schooler, N. R., Kalali, A. H., Alphs, L. D., Anand, R., Awad, G. A., Davidson, M., Dubé, S., Ereshefsky, L., Gharabawi, G. M., et al. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn110 · Cited by 151

Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?

Schoepp, D. D., & Marek, G. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606177 · Cited by 100

Translational research in central nervous system drug discovery

Hurko, O., & Ryan, J. L. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.671 · Cited by 96

Metabotropic Glutamate 2 (mGlu2) Receptors and Schizophrenia Treatment

González‐Maeso, J. (2017) · The Receptors · doi:10.1007/978-3-319-56170-7_4 · Cited by 3

Psychopharmacological Approaches

Citrome, L. (2013) · doi:10.1007/978-1-908517-88-3_5 · Cited by 3

Treatment of Schizophrenia in the 21st Century: Towards a more Personalised Approach

Hunter, R. (2012) · InTech eBooks · doi:10.5772/36078 · Cited by 2

Clinical Need and Rationale for Multi-Target Drugs in Psychiatry

Shahid, M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00014 · Cited by 2

Dopamine and Response to Antipsychotic Medication

Ntephe, C., & Demjaha, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_14 · Cited by 2

The role of thalamic group II mGlu receptors in health and disease

Copeland, C. S., & Salt, T. E. (2022) · Neuronal Signaling · doi:10.1042/ns20210058 · Cited by 2

Crosstalk Between 5-HT2A and mGlu2 Receptors: Implications in Schizophrenia and Its Treatment

Moreno, J. L., & González‐Maeso, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70474-6_7 · Cited by 2

Pharmacogenetics and Cognitive Symptoms in Schizophrenia Patients Treated with Antipsychotics

Musil, R., & Spellmann, I. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0083 · Cited by 2

Compound Attrition in Phase II/III

Alex, A., Harris, C., Keighley, W. W., & Smith, D. A. (2015) · doi:10.1002/9781118819586.ch4 · Cited by 2

Novel Targets for Drug Treatment in Psychiatry

Kurita, M., García‐Bea, A., & González‐Maeso, J. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_30 · Cited by 1

Lights and shadows of schizophrenia therapy research: Lessons from oral risperidone and olanzapine

Nicotra, E. F., Lecca, D., Casu, G., Palomba, M., Sil, A., & Marchese, G. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119900980 · Cited by 1

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

Nguyen, T. V. H., McKernan, D. P., & Kelly, J. P. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70284 · Cited by 1

Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far

Diendorfer, C., Bum, C., Weidenauer, A., Sauerzopf, U., Bartova, L., Dajic, I., Müller, L., Rujescu, D., Praschak-Rieder, N., & Willeit, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1766485 · Cited by 1

Genes and Schizophrenia: From a Festschrift Seminar Honoring William T. Carpenter Jr, MD

Malhotra, A. K. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt135 · Cited by 1

Symptômes négatifs de la schizophrénie : nouvelles approches pharmacologiques

Lodovighi, M.-A., Palomba, A., Belzeaux-R, R., Adida, M., & Azorin, J. (2015) · L Encéphale · doi:10.1016/s0013-7006(16)30010-0 · Cited by 1

Phase II and III drugs for the treatment of fragile X syndrome

Politte, L. C., & McDougle, C. J. (2012) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2013.750240 · Cited by 1

Glutamatergic Approaches for the Treatment of Schizophrenia

Morrow, J. A., Gilfillan, R. F., & Neale, S. A. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00056 · Cited by 1

Modeling Gene–Gene Interactions in Schizophrenia

Cheong, E. V., & O’Tuathaigh, C. M. P. (2015) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00019-5 · Cited by 1

Elucidation of molecular kinetic schemes from macroscopic traces using system identification

Fribourg, M., Logothetis, D. E., González‐Maeso, J., Sealfon, S. C., Iragüen, B. G., Andrés, F. L.-H., & Březina, V. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005376 · Cited by 1

Modulation of Metabotropic Glutamate Receptors by Orthosteric, Allosteric, and Light-Operated Ligands

Goudet, C., Rovira, X., Rondard, P., Pin, J., Llebaria, A., & Acher, F. (2018) · Topics in medicinal chemistry · doi:10.1007/7355_2017_32 · Cited by 1

Drugs Acting on Central Nervous System

Chakraborty, D., & Das, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-2776-6_5 · Cited by 1

Glutamate, Glutamatergic Drugs and Schizophrenia

Muguruza, C., & Callado, L. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_17 · Cited by 1

The Contribution of System Xc-to Prefrontal Cortical Mediated Behaviors Associated with Schizophrenia

Lutgen, V. (2012) · e-Publications@Marquette (Marquette University) · Cited by 1

Reply to Dr Seeman’s Comments on “A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia”

Kinon, B. J. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824ac357 · Cited by 1

The use of adjuvant L-arginine in schizophrenia: A behavioural and neurochemical analysis

MacKay, M.-A. B. (2016) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3zs2kq4m · Cited by 1

Novel approaches for treating schizophrenia

Davis, M. C., & Marder, S. R. (2012) · doi:10.2217/ebo.12.31 · Cited by 1

Behavioural and pharmacological characterization of a mouse model for psychotic disorders focus on glutamatergic transmission

Maksimovic, M. (2015) · Työväentutkimus Vuosikirja

Konzeption und Grundlagen einer funktionalen Psycho pharmako therapie

Gründer, G., & Benkert, O. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_1

Comment on: “Effects of a novel mGlu2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid” (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, Psychopharmacology, 2012)

Seeman, P. M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2687-z

Novel Treatments of Psychosis

Dunn, W., & Marder, S. R. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0032-7

Utility of Combined Treatment with Antipsychotic and Antidepressant Drugs: Scientific Rationales and Clinical Implications

Björkholm, C. (2013) · Figshare

Glutamate drug reduces dopamine inhibition of phosphorylation

Su, P., Lu, J., Seeman, P. M., & Liu, F. (2015) · Synapse · doi:10.1002/syn.21874

Discovery of novel antipsychotics targeting group II metabotropic glutamate receptor

Hiyoshi, T., Chaki, S., & Okuyama, S. (2012) · Folia Pharmacologica Japonica · doi:10.1254/fpj.140.111

Drugs that Target the Glutamate Synapse: Implications for the Glutamate Hypothesis of Schizophrenia

Mielnik, C. A., & Ramsey, A. J. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622499-00115

"Danger Will Robinson!" - Intra-Cellular Therapies Stock Soars While Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing

July, P. (2015)

Receptors and Related Drug Development for Schizophrenia: Research Advances

贾, 晓. (2016) · Pharmacy Information · doi:10.12677/pi.2016.52004

Prijedlog sveučilišnog poslijediplomskog specijalističkog studija OFTALMOLOGIJA I OPTOMETRIJA

Fakultet, M. (2013)

Prijedlog sveučilišnog poslijediplomskog specijalističkog studija ENDOKRINOLOGIJA I DIJABETOLOGIJA

Fakultet, M. (2013)

Receptors and Related Drug Development for Schizophrenia: Research Advances

Jia, X.-F., He, L., & Jiangsu, N. (2016)

mGlu2 Receptor Positive Allosteric Modulators

Trabanco, A. A., Cid, J. M., & Tresadern, G. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782629276-00156

Modulation of N-methyl-D-aspartate receptors by Gαs- and Gαi/o-coupled receptors

Trepanier, C. H. (2013) · TSpace (University of Toronto)

Screening of a Histone Methyltransferase Inhibitor in Animal Models of Psychiatric Illness

Kosowan, J. (2014) · TSpace (University of Toronto)

Dissecting the cellular mechanisms of NMDA receptor antagonist-induced disruptions to working memory and gamma oscillations

Sokolenko, E. (2019) · Minerva Access (University of Melbourne)

Development of an Analytical Tool to Characterize the Dynamics of Biological Systems Using Electrophysiological Traces

Fribourg, M. (2019) · doi:10.20868/upm.thesis.57438

A common molecular mechanism for cognitive deficits and craving in alcoholismPreprint

Meinhardt, M. W., Pfarr, S., Rohleder, C., Vengeliene, V., Barroso-Flores, J., Hoffmann, R., Meinhardt, M. L., Paul, E. R., Hansson, A. C., Köhr, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.13.200519

Faculty Opinions recommendation of Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.

Jockers, R. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13409956.14781055

Discovery of Subtype Selective Agonists of the Group II Metabotropic Glutamate Receptors

Hao, J. (2022) · doi:10.1002/9781119627784.ch6

Novel Approaches for Treating Psychotic Disorders

Marques, T. R., & Kapur, S. (2017) · doi:10.1093/med/9780190681425.003.0021

Chapter 2. Neurotransmitters, Receptors, and Transporters

Berg, K. A., Clarke, W. P., Daws, L. C., Frazer, A., Girotti, M., & Lodge, D. J. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as02

A Comprehensive Review on the Screening Models for the Pharmacological Assessment of Antipsychotic Drugs

Singh, Y., Rai, N., & Wal, P. (2024) · Current Materials Science · doi:10.2174/0126661454326790241014031752

Dusting off old blueprints: Is it time to reconsider metabotropic glutamate receptor 2 for therapeutic drug development?

Bespalov, A., Lütjens, R., & Doller, D. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173908

Unmet Promise or Missed Potential? A pairwise and network meta-analysis on efficacy and safety of metabotropic glutamate receptor agonists and positive allosteric modulators in schizophrenia

Mishra, A., Shaju, A., Ibrahimpur, N. S., Mishra, B. R., Srinivasan, A., & Maiti, R. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.023

IDENTIFYING DRUG TARGETS FOR SCHIZOPHRENIA THROUGH GENE PRIORITIZATION

Heilbron, K., Kraft, J., Braun, A., Awasthi, S., Panagiotaropoulou, G., Schipper, M., Bell, N. Y., Posthuma, D., Pardiñas, A. F., & Ripke, S. (2024) · Translational Psychiatry · doi:10.1016/j.euroneuro.2024.08.036 · Cited by 4

Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia

Harris, N. M., Holter, K. M., & Niswender, C. M. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.06.012

Beyond dopamine: KarXT and emerging mechanism-based therapies in schizophrenia

Żuraw, I., Urbański, K., Kogut, P., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1828831

BindingDB Entry 50046617: Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective

BindingDB (2016) · UC San Diego · doi:10.7270/q29s1st0

BindingDB Entry 50047041: Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis.

BindingDB (2017) · UC San Diego · doi:10.7270/q2nv9m4s

BindingDB Entry 50000267: Synthesis and Pharmacological Characterization of C4

BindingDB (2019) · UC San Diego · doi:10.7270/q2w95cm9

BindingDB Entry 50014489: Positive allosteric modulators (PAMs) of the group II metabotropic glutamate receptors: Design, synthesis, and evaluation as ex-vivo tool compounds.

BindingDB (2022) · UC San Diego · doi:10.7270/q22f7s71

BindingDB Entry 50045233: Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor.

BindingDB (2016) · UC San Diego · doi:10.7270/q2dj5h8j

Neuronal nicotinic receptors as targets for enhancing cognition in schizophrenia

Rushforth, S. L. (2013)

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia

Downing, A. M., Kinon, B. J., Millen, B. A., Zhang, L., Liu, L., Ma, M., Brenner, R., Rayle, T. J., Nisenbaum, L., Zhao, F., et al. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0351-3 · Cited by 129

mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial

Mosolov, S. N., Ab, S., Незнанов, Н. Г., Tochilov, V. A., Andreev, B. V., Аведисова, А. С., Bardenshteyn, L. M., Gurovich, I., Reznik, A. M., Nb, Z., et al. (2011) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-011-9455-0 · Cited by 1

Comment on “A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia” by Kinon et al

Seeman, P. M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318248daaa · Cited by 7

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040

Reply to Dr Seeman’s Comments on “A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia”

Kinon, B. J. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824ac357 · Cited by 1